Compare Aurobindo Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs UNICHEM LAB - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA UNICHEM LAB AUROBINDO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 14.7 61.9 23.7% View Chart
P/BV x 3.2 0.7 479.3% View Chart
Dividend Yield % 0.4 2.1 18.9%  

Financials

 AUROBINDO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
UNICHEM LAB
Mar-19
AUROBINDO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs809292 277.1%   
Low Rs504182 276.9%   
Sales per share (Unadj.) Rs281.1167.7 167.6%  
Earnings per share (Unadj.) Rs41.4-3.6 -1,139.0%  
Cash flow per share (Unadj.) Rs50.95.9 856.3%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.41.7 22.6%  
Book value per share (Unadj.) Rs199.4372.3 53.6%  
Shares outstanding (eoy) m585.8870.38 832.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.31.4 165.3%   
Avg P/E ratio x15.9-65.3 -24.3%  
P/CF ratio (eoy) x12.939.9 32.3%  
Price / Book Value ratio x3.30.6 517.2%  
Dividend payout %6.0-110.2 -5.5%   
Avg Mkt Cap Rs m384,63016,680 2,305.9%   
No. of employees `00017.32.6 666.1%   
Total wages/salary Rs m21,3082,393 890.4%   
Avg. sales/employee Rs Th9,500.74,535.2 209.5%   
Avg. wages/employee Rs Th1,229.4919.8 133.7%   
Avg. net profit/employee Rs Th1,397.9-98.2 -1,423.5%   
INCOME DATA
Net Sales Rs m164,66611,801 1,395.4%  
Other income Rs m1,020984 103.6%   
Total revenues Rs m165,68612,785 1,296.0%   
Gross profit Rs m37,718-835 -4,517.6%  
Depreciation Rs m5,580674 828.2%   
Interest Rs m77775 1,033.5%   
Profit before tax Rs m32,380-600 -5,399.4%   
Minority Interest Rs m310-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183-343 -2,382.4%   
Profit after tax Rs m24,229-256 -9,481.9%  
Gross profit margin %22.9-7.1 -323.7%  
Effective tax rate %25.357.3 44.1%   
Net profit margin %14.7-2.2 -679.5%  
BALANCE SHEET DATA
Current assets Rs m121,87820,384 597.9%   
Current liabilities Rs m86,8065,029 1,726.1%   
Net working cap to sales %21.3130.1 16.4%  
Current ratio x1.44.1 34.6%  
Inventory Days Days130105 124.0%  
Debtors Days Days68135 50.7%  
Net fixed assets Rs m81,0379,023 898.1%   
Share capital Rs m586141 416.1%   
"Free" reserves Rs m116,21826,058 446.0%   
Net worth Rs m116,80426,199 445.8%   
Long term debt Rs m4,5120-   
Total assets Rs m211,05231,496 670.1%  
Interest coverage x42.7-7.0 -611.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.4 208.2%   
Return on assets %11.8-0.6 -2,069.4%  
Return on equity %20.7-1.0 -2,126.8%  
Return on capital %27.4-2.0 -1,368.3%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7278,188 985.9%   
Fx outflow Rs m34,700596 5,822.2%   
Net fx Rs m46,0277,592 606.3%   
CASH FLOW
From Operations Rs m19,548-3,278 -596.4%  
From Investments Rs m-19,570-2,860 684.2%  
From Financial Activity Rs m8,642-24 -35,708.7%  
Net Cashflow Rs m8,922-4,690 -190.2%  

Share Holding

Indian Promoters % 54.1 50.1 108.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 15.1 52.6%  
FIIs % 27.7 3.0 923.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 31.7 32.2%  
Shareholders   69,601 20,176 345.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  GLENMARK PHARMA  SUN PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS